Tepotinib
- Generic Name
- Tepotinib
- Brand Names
- Tepmetko
- Drug Type
- Small Molecule
- Chemical Formula
- C29H28N6O2
- CAS Number
- 1100598-32-0
- Unique Ingredient Identifier
- 1IJV77EI07
- Background
Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma, gastric cancers, non-small cell lung cancer, and hepatocel...
- Indication
Tepotinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
MET Targeting Therapies Market Set for Significant Growth
The MET targeting therapies market is poised for significant growth by 2034 due to rising cancer diagnoses, increased awareness, and numerous therapies in clinical trials. Key players include AstraZeneca, AbbVie, and Regeneron, with therapies like ORPATHYS and Telisotuzumab Vedotin in development. Regulatory approvals and precision medicine advancements are driving market dynamics, though challenges like pricing and reimbursement persist.
China's National Reimbursement Drug List (NRDL) outlook for 2024
The National Reimbursement Drug List (NRDL) faces budget pressure and competition, with 445 drugs passing formal review in 2024. Oncology, immunology, neurology, and rare diseases see strategic positioning and comparator choices as key. Contract renewals and re-negotiations are under pressure, emphasizing clear messaging and data preparation for NRDL success.
FDA OKs FoundationOne Liquid CDx for Tepotinib in METex14-Skipping NSCLC
FDA approves FoundationOne Liquid CDx as a companion diagnostic to identify mNSCLC patients with MET exon 14 skipping alterations for tepotinib treatment.
Related Clinical Trials:
Revisit Every OncLive On Air Episode From October 2024
October 2024 episodes of OncLive On Air discussed FDA approvals for durvalumab in resectable NSCLC, tepotinib in MET+ NSCLC, vorasidenib in IDH1/2+ grade 2 astrocytoma/oligodendroglioma, denileukin diftitox in relapsed/refractory CTCL, and updates on myelofibrosis, hepatobiliary and CRC management, liquid biopsy in NSCLC, and quality of life outcomes in CRC.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath